This Article Abstract Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hagemeister, F. Articles by Zinzani, P. L. Search for Related Content PubMed PubMed Citation Articles by Hagemeister, F. Articles by Zinzani, P. L.

The Role of Mitoxantrone in the Treatment of Indolent Lymphomas

^a The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; ^b Auxilio Muto Cancer Center, San Juan, Puerto Rico; ^c Weill Medical College of Cornell University, New York, New York, USA; ^d Rush University Medical Center, Chicago, Illinois, USA; ^e University of Bologna, Bologna, Italy

Correspondence: Fredrick Hagemeister, M.D., The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Telephone: 713-792-2860; Fax: 713-794-5656; e-mail: fhagemei{at}mdanderson.org

	LEARNING OBJECTIVES

Top Learning Objectives Abstract Introduction Indolent Lymphomas: Single-Agent... Mitoxantrone-Containing... Conclusions and Future... References

 
After completing this course, the reader will be able to:

1. Describe three regimens that use mitoxantrone in indolent lymphoma.
   
2. List the NCCN-recommended regimens for the first-line treatment of follicular lymphoma.
   
3. Discuss the side-effect profile of mitoxantrone in combination with other agents for indolent lymphoma.
   

	ABSTRACT

Top Learning Objectives Abstract Introduction Indolent Lymphomas: Single-Agent... Mitoxantrone-Containing... Conclusions and Future... References

 
With the introduction of newer therapeutic approaches, survival in indolent non-Hodgkin’s lymphoma (NHL) appears to be improving. Mitoxantrone (Novantrone^®; Serono, Inc.; Rockland, MA, http://www.seronousa.com), an anthracenedione with low cardiotoxic potential, has demonstrated activity in indolent NHL in combination with fludarabine (Fludara^®; Berlex Laboratories; Wayne, NJ, http://www.berlex.com) and other agents. In a Southwest Oncology Group trial (SWOG 9501), treatment with fludarabine and mitoxantrone (FM) induced a complete remission (CR) rate of 44% and a partial remission (PR) rate of 50% in untreated patients. The estimated 4-year progression-free survival (PFS) rate was 38%. In a multicenter Italian trial comparing the efficacy of FM with that of cyclophosphamide, doxorubicin (Adriamycin^®; Bedford Laboratories; Bedford, OH, http://www.bedfordlabs.com), vincristine (Oncovin^®; Eli Lilly and Company; Indianapolis, IN, http://www.lilly.com), and prednisone (Deltasone^®; Pfizer Pharmaceuticals; New York, NY, http://www.pfizer.com), CHOP, followed by rituximab (Rituxan^®; Genentech, Inc.; South San Francisco, CA, http://www.gene.com) for patients with incomplete clinical or molecular responses, the CR and molecular response rates were significantly higher in the FM arm, but the PFS and overall survival (OS) rates did not differ between the two arms. However, FM was also significantly less toxic than CHOP. The administration of rituximab following chemotherapy resulted in higher clinical and molecular response rates in both arms. In a separate trial, FM plus dexamethasone (Decadron^®; Merck and Co., Inc.; Whitehouse Station, NJ, http://www.merck.com), FND, plus concurrent rituximab produced a CR rate of 92%. In a randomized German study, patients with indolent lymphomas received FM plus cyclophosphamide (FCM) or FCM with rituximab. PFS and OS times were significantly better for patients who received combined chemoimmunotherapy. Mitoxantrone-based regimens are highly active and well tolerated in patients with both relapsed and previously untreated indolent lymphomas. The addition of rituximab appears to increase the activity of the FM, FND, and FCM regimens. Although the results of the Italian multicenter study support the superiority of FM over CHOP in terms of clinical and molecular responses and tolerability, additional studies using rituximab in combination with both of these regimens should be attempted to determine the possible further benefit of both in the management of indolent lymphoma. Because cure remains elusive in patients with indolent lymphoma, maximum prolongation of PFS with minimal toxicity and maximum preservation of quality of life should remain central goals of treatment.

Key Words. Mitoxantrone • Indolent lymphoma • Combination therapy • Rituximab • Progression-free survival

	INTRODUCTION

Top Learning Objectives Abstract Introduction Indolent Lymphomas: Single-Agent... Mitoxantrone-Containing... Conclusions and Future... References

 
Indolent lymphomas constitute 30%–35% of all non-Hodgkin’s lymphoma (NHL) subtypes. Of these, follicular lymphoma is the most common form of indolent lymphoma, found in the vast majority of patients [1, 2]. Approximately 54,000 new cases of NHL are expected in the U.S. in 2004 [3]. For reasons that are incompletely understood, the incidence of NHL has been rising over the past 10 years, with the sharpest rate of increase in individuals aged 65 years and older [4]. As the population ages, the incidence of NHL is expected to further increase. For this reason, more patients with indolent NHL may be expected to have significant medical comorbidities in the future, creating new challenges to therapy of these diseases.

Historically, the course of indolent lymphoma is characterized by initial responsiveness to a variety of treatment approaches, with good response rates, but frequent relapses. Most patients with indolent lymphomas appear to have diseases that progress so slowly that delayed treatment is a management option, justifying a "watch and wait" approach to the initial treatment. However, over time, clinical progression occurs in almost all patients, and median survival rates with standard regimens such as cyclophosphamide, doxorubicin (Adriamycin^®; Bedford Laboratories; Bedford, OH, http://www.bedfordlabs.com), vincristine (Oncovin^®; Eli Lilly and Company; Indianapolis, IN, http://www.lilly.com), and prednisone (Deltasone^®; Pfizer Pharmaceuticals; New York, http://www.pfizer.com), CHOP, range from 5–10 years in large series [1, 2, 5, 6]. More recently, with the introduction of newer therapeutic approaches, improved 10-year survival rates (37%–60%) have been reported in some studies [7]. A recent trial using combination therapy with fludarabine (Fludara^®; Berlex Laboratories; Wayne, NJ, http://www.berlex.com), mitoxantrone (Novantrone^®; Serono, Inc.; Rockland, MA, http://www.seronousa.com), and dexamethasone (Decadron^®; Merck and Co., Inc.; Whitehouse Station, NJ, http://www.merck.com), FND, plus rituximab (Rituxan^®; Genentech, Inc.; South San Francisco, CA, http://www.gene.com) demonstrated a 3-year overall survival (OS) rate of 95% and a 5-year failure-free survival (FFS) rate of 70% [8, 9]. Additional studies are required to confirm these findings.

Current National Comprehensive Cancer Network (NCCN)-recommended regimens for the first-line treatment of follicular lymphoma include: single-agent therapy with rituximab, chlorambucil (Leukeran^®; GlaxoSmithKline; Philadelphia, PA, http://www.gsk.com), or cyclophosphamide; single-agent fludarabine with or without rituximab; combination treatment with cyclophosphamide, vincristine (Oncovin^®; Eli Lilly and Company), and prednisone (Deltasone^®; Pfizer Pharmaceuticals), CVP, or CHOP with or without rituximab; and combination treatment with FND with or without rituximab. Because the choice of initial therapy is influenced by multiple factors, such as age, patient comorbidities, and future treatment possibilities (e.g., autologous stem cell transplant), treatment selection may be individualized. Recommendations for second-line treatment include: radioimmunotherapy, for patients who have had no prior stem cell transplant and have adequate bone marrow reserve; autologous or allogeneic stem cell transplant; and chemoimmunotherapy regimens, as described for initial therapy (Table 1) [10].

In this report, we review recent data on the use of mitoxantrone-containing regimens in the treatment of indolent NHL.

	INDOLENT LYMPHOMAS: SINGLE-AGENT THERAPIES

Top Learning Objectives Abstract Introduction Indolent Lymphomas: Single-Agent... Mitoxantrone-Containing... Conclusions and Future... References

 
A variety of drugs are active in the treatment of indolent lymphomas both as single agents and in combination with other drugs. Single-agent therapy has been employed as a standard of treatment in indolent lymphoma for many years. The characteristics of mitoxantrone in combination with several agents suggest that this drug has significant activity in the treatment of indolent lymphomas.

Mitoxantrone
Mitoxantrone, an anthracenedione compound, has a spectrum of clinical activity similar to that of the anthracyclines. It lacks the amino sugar of doxorubicin and the characteristic ring structure of classical anthracyclines. On the basis of these modifications, it was predicted that mitoxantrone would retain the antineoplastic activity of the anthracycline class with less potential for cardiotoxicity [12, 13]. Preclinical studies demonstrated that mitoxantrone inhibits topoisomerase II, interferes with RNA synthesis, and intercalates with DNA, resulting in strand breaks and crosslinking [12, 14]. Mitoxantrone also has demonstrated potent activity in preclinical lymphoma models and appears clinically active against both aggressive and follicular lymphomas [15–17].

Mitoxantrone is clinically associated with a much lower cardiotoxic risk than is doxorubicin. Although the mechanism of mitoxantrone-induced cardiotoxicity is not certain, anthracycline-associated cardiotoxicity appears to be caused by activated oxygen-free radicals; in vitro, mitoxantrone has been shown to generate free radicals to a much lesser degree than doxorubicin [18]. In a comparative trial of patients with advanced breast cancer treated with either cyclophosphamide, doxorubicin, and fluorouracil (CAF) or cyclophosphamide, mitoxantrone, and fluorouracil (CNF), investigators observed significantly less cardiotoxicity in the group receiving CNF [13].

Fludarabine
Fludarabine, one of the purine analogues, is an antimetabolite with significant activity against chronic lymphocytic leukemia and indolent lymphomas. Phase I and phase II trials of fludarabine in patients with relapsed and refractory follicular lymphomas demonstrated response rates of 30%–60% [19–21]. When combined in vitro, fludarabine and mitoxantrone exert synergistic effects [22]. In a study of patients with relapsed or refractory indolent lymphomas who received fludarabine, mitoxantrone, and dexamethasone, complete response (CR) and partial response (PR) rates were 47% and 47%, respectively. Acute nonhematologic toxicities, such as nausea and vomiting, were modest. The major adverse effect was myelosuppression. Opportunistic infections with Pneumocystis carinii and Herpes zoster were seen. On the basis of these promising results, investigators began clinical trials of FND in previously untreated patients with indolent lymphomas [23].

Rituximab
Rituximab, a chimeric mouse/human antibody directed against CD20, is an important therapeutic option for patients with B-cell lymphomas. In preclinical studies, rituximab lysed CD20⁺ cells via human-complement or antibody-dependent cell-mediated cytotoxicity and induced apoptosis in the presence of either goat antimouse IgG or Fc receptor–expressing cells [24]. Many investigators have demonstrated that single-agent rituximab has significant clinical activity in pretreated patients with follicular lymphomas. In one study, patients with follicular lymphomas who received first-line single-agent rituximab had a clinical response rate of 73% and a molecular response rate of 62% at 1 year [24]. Rituximab has now been combined with many different chemotherapy regimens. When this antibody was combined with CHOP, CRs were seen in 50%–60% of patients and PRs were seen in 30%–40% [25–28]. Similar synergy was observed when rituximab was combined with fludarabine both in vitro and in vivo [27]. These regimens, and others, appear to result in longer disease-free survival times for patients with indolent lymphomas when compared with patients who receive chemotherapy alone. However, no study has unequivocally demonstrated superior survival rates using the combination of rituximab and chemotherapy. Toxicities following rituximab chemotherapy combinations were generally similar to those occurring with these regimens when administered without rituximab, indicating an absence of overlapping toxicities.

Cyclophosphamide
Cyclophosphamide, the most frequently used alkylating agent in the treatment of lymphomas, was first described as therapy for diffuse large-cell lymphoma in 1975 [29]. The CHOP regimen subsequently became standard treatment for patients with aggressive lymphomas and is also frequently used by clinicians to treat indolent lymphomas [5]. However, the standard CHOP regimen has not been proven to be capable of eradicating MRD in patients with follicular lymphomas, as documented by the persistence of cells bearing the bcl-2 gene rearrangement in blood and marrow. This observation has encouraged the investigation of cyclophosphamide in combination with newer agents, such as rituximab, fludarabine, and mitoxantrone, in patients with relapsed disease [26, 30].

	MITOXANTRONE-CONTAINING COMBINATION REGIMENS

Top Learning Objectives Abstract Introduction Indolent Lymphomas: Single-Agent... Mitoxantrone-Containing... Conclusions and Future... References

 
Besides its activity as a single agent in the treatment of patients with follicular lymphomas, investigators have reported responses with mitoxantrone in combination with fludarabine, with or without dexamethasone, that appear better than those obtained with single-agent fludarabine in similar patient populations [5, 23]. Four clinical trials using combinations of mitoxantrone and fludarabine (FM) were reported recently (Table 2). In one, FM was administered alone [6], whereas the other three trials used concomitant or sequential administration of rituximab. Of these latter three, one included a randomized comparison of FM and CHOP followed by rituximab in selected patients in both arms [31]. In the remaining two trials, FM was also combined with either dexamethasone (FND) or cyclophosphamide (FCM) [8, 30].

Seventy-eight eligible patients were enrolled in the study. Forty-four percent attained CRs and 50% had PRs. The median PFS was 32 months, and the estimated 4-year PFS rate was 38%. The median overall survival time had not been reached with 88% of the patients alive at 4 years. Molecular response rates were not studied. The FM regimen was generally well tolerated, with infrequent mild gastrointestinal toxicities being the predominant nonhematologic side effects. Reversible myelosuppression was the major toxicity, with grades 3 and 4 neutropenic episodes occurring in 27 patients. Although 10 patients had documented infections, including three episodes of Herpes zoster in patients who received 4–8 cycles of chemotherapy, no life-threatening or fatal opportunistic infections occurred.

Overall, the SWOG trial indicated that FM is an effective, well-tolerated regimen for the treatment of patients with advanced indolent lymphomas. Although cross-trial comparisons can be misleading, the PFS with this regimen was similar to those reported with prior anthracycline-based SWOG regimens. Because this trial did not include dexamethasone, it is not possible to determine whether the efficacy of the FND regimen is equivalent to that of the CHOP regimen. The estimated 4-year OS rate in this trial was somewhat better than those reported from previous SWOG trials, but this result could possibly be attributed to an effect of better salvage therapy.

FM with or without Rituximab Versus CHOP with or without Rituximab as Front-Line Therapy for Patients with Advanced Follicular Lymphomas
Italian investigators performed a study to compare the efficacies of the FM and CHOP chemotherapy regimens, as measured by clinical and molecular response rates [31]. In that study, selected patients received rituximab following chemotherapy in both arms. The choice of whether to administer rituximab was based on clinical and molecular restaging: patients who achieved both clinical and molecular CRs did not receive rituximab; patients who achieved a clinical CR without a molecular CR or a PR with or without a molecular CR were treated with sequential rituximab immunotherapy; nonresponding patients went off study. Patients received either FM or CHOP at conventional doses, but with cycles repeated every 21 days (Fig. 1). Patients did not receive prophylaxis for Pneumocystis carinii infection. The primary study end points were the clinical CR rates with each regimen; secondary end points included molecular response, comparison of outcomes with and without rituximab, and OS, relapse-free survival, and PFS rates [31].

View larger version (24K): [in this window] [in a new window]   Figure 1. Study design of Italian multicenter trial of FM versus CHOP therapy in patients with follicular lymphomas. Abbreviations: CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone; CR = complete response; FM = fludarabine and mitoxantrone; NR = no response; PR = partial response. Reprinted with permission from the American Society of Clinical Oncology ( Zinzani PL, Pulsoni A, Perrotti A et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654–2661).

FND and Concurrent Rituximab Versus FND Followed by Sequential Rituximab as Initial Therapy for Indolent Lymphomas
In a randomized trial, investigators studied the FND regimen, with rituximab given concurrently (concurrent FND+R) or sequentially (sequential FND+R), as initial therapy in patients with stage IV small lymphocytic or follicular lymphomas. All patients who responded after completing chemotherapy received maintenance interferon-2b for 1 year. FND was administered for eight courses, given every 28 days. The primary end point was molecular remission at 12 months. Secondary end points included FFS and OS rates, tolerability, and safety [8].

The investigators have reported results of therapy for 149 evaluable patients who had more than 12 months of follow-up. At a median follow-up of 30 months, 92% of the patients receiving concurrent treatment and 85% of the patients receiving sequential treatment achieved a clinical CR (p = 0.17). The molecular response rate at 1 year was high in both arms of the study, but significantly better for those who received concurrent FND+R (89% versus 68% for sequential FND+R; p = .01). The 3-year FFS times were 77 months for concurrent and 64 months for sequential therapy (p = 0.11); the 3-year OS rate was 95% in both groups. Both treatment schedules were well tolerated. Although there was a slightly higher incidence of grade 3–4 neutropenia with concurrent FND+R, there was no higher incidence of infection.

The results of that trial, conducted at the MD Anderson Cancer Center, suggest that concurrent FND+R results in a slightly higher 3-year FFS rate than sequential FND+R, although the difference was not statistically significant. However, for the subset of patients with follicular lymphomas, the 3-year FFS rate was significantly better for the concurrent FND+R arm than for the sequential FND+R arm (84% versus 59%; p = .01). Longer follow-up is needed to assess these results more fully, especially with regard to OS rates. Sample sizes were relatively small in this single-institution study, which was not powered to detect differences in FFS or OS. In addition, the effect of interferon and its schedule on results in both arms is unknown.

FCM and FCM with Rituximab for Recurrent Indolent Lymphomas
The German Low Grade Lymphoma Study Group performed a randomized trial comparing FCM plus rituximab (FCM+R) with FCM alone in the treatment of patients with relapsed or refractory follicular, lymphoplasmacytic, or mantle cell lymphomas. Since most patients had received CHOP chemotherapy as initial treatment, a fludarabine-containing regimen was chosen for salvage therapy. One hundred forty-seven patients received treatment, randomized to either FCM alone for four courses given every 28 days or FCM+R on day 1 of each cycle. Of the 126 evaluable patients, 52% had follicular lymphomas and 38% had mantle cell histology [30].

Sixty-one percent of patients receiving FCM alone achieved CRs (14%) or PRs (47%), compared with 82% (37% CR rate and 46% PR rate) for patients receiving FCM+R (p < .007). The PFS (p < .028) and OS (p < .002) rates were also significantly better for patients receiving FCM+R. While only a little more than one-third of the patients treated with the combined therapy achieved CRs, these results reflect the adverse prognostic impact of having failed combination chemotherapy and the inclusion of mantle cell histology. Although requiring confirmation in additional studies with larger numbers of patients, this was the first prospective randomized trial to demonstrate that combined immunochemotherapy in patients with relapsed follicular and mantle cell lymphomas is superior to chemotherapy alone, both in terms of response and survival rates.

Thiotepa, Vincristine, Prednisone, and Mitoxantrone plus Rituximab for Marginal Zone Lymphoma
Marginal zone lymphoma (MZL) is a small cell subtype of indolent lymphoma for which no standard therapy has been established. As previously discussed, mitoxantrone is associated with less cardiotoxicity and alopecia than doxorubicin. Thiotepa, likewise, does not induce alopecia and is not associated with the immunosuppressive properties of fludarabine. The combination of thiotepa, vincristine, prednisone, and mitoxantrone (TOP-M) has been shown to be useful in elderly patients with diffuse large cell lymphoma [32]. The TOP-M regimen, consisting of thiotepa (7.5 mg/m²), mitoxantrone (7.5 mg/m²), vincristine, and prednisone as per the CHOP regimen, and rituximab (375 mg/m²), all given on day 1 of a 21–28 day cycle (in accordance with resolution of cytopenias), was administered to 12 patients with disseminated MZL [33]. Four patients received TOP-M alone and eight received TOP-M plus rituximab. The doses of thiotepa and mitoxantrone were escalated by a total of 2.5 mg to a maximum of 20 mg/m² based on nadir blood counts. Four patients had stage III disease, eight had stage IV disease, four had B symptoms, and four had elevated lactate dehydrogenase levels. Treatment was well tolerated, with only two episodes of hospitalization for fever. There was no cardiac toxicity. Eleven of 12 patients (92%) had clinical responses, with nine (75%) confirmed and unconfirmed CRs (CR/CRu) and two (17%) PRs. The median duration of response had not been reached with a range of 11–40 months of follow-up. Based on these preliminary findings, TOP-M with rituximab appears to be a well-tolerated and active regimen for disseminated MZL and may have utility for the treatment of other indolent lymphomas.

	CONCLUSIONS AND FUTURE DIRECTIONS

Top Learning Objectives Abstract Introduction Indolent Lymphomas: Single-Agent... Mitoxantrone-Containing... Conclusions and Future... References

 
Mitoxantrone-based regimens are highly active and well tolerated in the treatment of patients with both relapsed and previously untreated indolent lymphomas. The Italian multicenter trial was the first randomized comparison of a fludarabine-based regimen with standard CHOP chemotherapy. In that trial, compared with CHOP, FM was associated with significantly higher clinical and molecular response rates and significantly better tolerability. Despite the superior clinical and molecular response rates, the FFS and OS rates were not better with FM therapy, possibly in part related to the treatment design of the study. The relatively small numbers of patients and short duration of median follow-up also make it difficult to interpret these survival data definitively. However, in other studies, investigators have found a significantly longer FFS in patients who achieve molecular responses within the first year of treatment, compared with those who still have positive molecular findings [11]. The addition of rituximab appears to increase the activity of FM regimens in patients with indolent NHL [31]. In the Italian multicenter trial, the sequential administration of rituximab produced higher clinical and molecular response rates in patients treated with FM. In the study of FND plus concurrent or sequential rituximab performed at the MD Anderson Cancer Center, concurrent FND+R resulted in a slightly higher 3-year FFS than sequential FND+R; these results were significantly better for the follicular lymphoma subset [8]. In the German Low Grade Lymphoma Study Group trial, combination chemoimmunotherapy with FCM+R was superior to FCM alone in terms of response, PFS, and OS rates [30]. To date, that trial provides the only direct comparative evidence supporting the addition of rituximab to mitoxantrone-based therapy for relapsed disease. Although chemotherapy and immunotherapy exert antitumor effects through different mechanisms of action, with generally nonoverlapping toxicities, additional research is needed to confirm the benefit of combined chemoimmunotherapy and to define optimal dosing schedules. The combination of these modalities offers an attractive approach to improving overall clinical outcomes in patients with low-grade lymphomas.

Mitoxantrone is associated with few significant grade 3–4 nonhematologic side effects. Because mitoxantrone has a lower cardiotoxic potential than doxorubicin, it may be advantageous to initially use mitoxantrone in the treatment of patients with indolent NHL, reserving doxorubicin for later use. However, this hypothesis has yet to be clinically tested. Mitoxantrone-based regimens can also be offered to patients who are concerned about anthracycline-associated alopecia. Central venous access is not required for the administration of mitoxantrone in any combination, since extravasation of this drug does not produce significant tissue injury or necrosis. Mitoxantrone also appears to be associated with less gastrointestinal toxicities than CHOP, including nausea and vomiting, abdominal pain, and constipation, making it an attractive drug to use in combination with fludarabine as therapy for older patients.

Because FM-based regimens use only 3 days of treatment with fludarabine, in contrast to 5 days with other fludarabine-containing regimens, FM may also be a preferable choice for patients who subsequently undergo autologous or allogeneic stem cell transplants. The primary toxicity of fludarabine is myelosuppression, which may be prolonged in some patients, especially in those receiving higher doses or prolonged therapy [19–21]. Given the greater potential for serious myelotoxicity associated with greater fludarabine exposure, a shorter 3-day course may be a safer alternative when given in combination with mitoxantrone.

A potential new approach is the sequential combination of chemotherapy with radioimmunotherapeutic agents, such as the anti-CD20 radioimmunoconjugates ¹³¹I-tositumomab and ⁹⁰Yttrium-ibritumomab-tiuxetan. Both agents have demonstrated activity in patients with follicular lymphomas refractory to both prior chemotherapy and rituximab [34–37]. New studies combining mitoxantrone-containing regimens with radioimmunoconjugates are planned and may add to our knowledge of the benefit of these drugs.

Despite therapeutic progress, cure remains the ultimate goal for patients with indolent lymphomas. Whether this can be achieved now is conjectural; however, prolongation of life, enhanced quality of life with PFS, and minimizing toxicity are goals equally important and hopefully achievable.

Brief Patient Case
A 56-year-old female executive of a high fashion magazine fortuitously noticed a 2.5-cm left supraclavicular node while dressing. Her history includes rheumatic fever and murmur as a child as well as smoking 1–2 packs of cigarettes per day for 30 years. A computed axial tomography (CAT) scan disclosed hilar lymphadenopathy but clear lung fields and she was asymptomatic. A node biopsy established the diagnosis of follicular, grade one lymphoma. Work-up revealed 1–2 cm nodes in the inguinal area, but all laboratory data were otherwise unrevealing. The patient emphasized that she must maintain her appearance and hectic pace for the next several years and was managed with observation. After 1.5 years, she presented with a history of rapidly growing peripheral nodes and weight loss. Evaluation disclosed no evidence of transformation; however, a CAT scan showed significant abdominal lymphadenopathy with some impingement on the ureters and moderate bilateral hydronephrosis. There was also a 20-cm enlarged spleen with some pressure effects on the stomach. Cardiac evaluation showed a multigated acquisition (MUGA) scan ejection fraction of 55%. Creatinine clearance was 55 ml/minute. The patient was treated with FM+R in order to achieve a rapid response. She had an excellent response, remained in response for 20 months, and was able to maintain her current lifestyle during and after treatment.

	ACKNOWLEDGMENT

Top Learning Objectives Abstract Introduction Indolent Lymphomas: Single-Agent... Mitoxantrone-Containing... Conclusions and Future... References

 
Dr. Hagemeister is a member of the Speakers Bureau for OSI Pharmaceuticals. Dr. Gregory receives grant/research support from Corixa, IDEC, Genentech, Amgen, Genta, Millennium, and Ortho Biotech, serves as an educator for Corixa, IDEC, Genentech, Genta, Ortho Biotech, and GlaxoSmithKline, and serves as a consultant for Corixa, IDEC, Genentech, Amgen, Genta, and Ortho Biotech.

	REFERENCES

Top Learning Objectives Abstract Introduction Indolent Lymphomas: Single-Agent... Mitoxantrone-Containing... Conclusions and Future... References

 

1. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997;89:3909–3918.[Abstract/Free Full Text]
2. Armitage JO, Weisenburger D. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998;16:2780–2795.[Abstract]
3. American Cancer Society. Cancer Facts and Figures 2004. NCI SEER program. Available at http://www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf. Accessed November 24, 2004.
4. Vose JM, Chiu BC, Cheson BD et al. Update on epidemiology and therapeutics for non-Hodgkin’s lymphoma. Hematology (Am Soc Hematol Educ Program) 2002:241–262
5. McLaughlin P. Progress and promise in the treatment of indolent lymphomas. The Oncologist 2002;7:217–225.[Abstract/Free Full Text]
6. Velasquez WS, Lew D, Grogan TM et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 2003;21:1996–2003.[Abstract/Free Full Text]
7. Liu Q, Fayad L, Hagemeister FB et al. Stage IV indolent lymphoma: 25 years of treatment progress. Blood 2003;102:398a, abstract 1446.
8. McLaughlin P, Rodriguez MA, Hagemeister FB et al. Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab monoclonal antibody therapy, with interferon maintenance. Proc Am Soc Clin Oncol 2003;102:564, abstract 2269.
9. Jiang Y, McLaughlin P, Thomaides A et al. Quantification and monitoring of the T(14;18) translocation copy number by real-time PCR in patients with follicular lymphoma treated with FND plus concurrent or delayed rituximab. Blood 2003;102:1444a.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, v.1.2004. Non-Hodgkin’s Lymphoma. Jenkintown, PA: NCCN, 2004. Available at http://www.nccn.org. Accessed November 24, 2004.
11. López-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998;91:2955–2960.[Abstract/Free Full Text]
12. Wallace RE, Murdock KC, Angier RB et al. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl) amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 1979; 39:1570–1574.[Abstract/Free Full Text]
13. Bennett JM, Muss HB, Doroshow JH et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988;6:1611–1620.[Abstract/Free Full Text]
14. Armitage JO. The role of mitoxantrone in non-Hodgkin’s lymphoma. Oncology (Huntingt) 2002;16:490–502, 507–508, discussion 511–512, 514.
15. Coltman CA Jr, Coltman TM, Balcerzak SP et al. Mitoxantrone in refractory nonHodgkin’s lymphoma. A Southwest Oncology Group study. Semin Oncol 1984;11(suppl 1):50–53.[Medline]
16. Gams RA, Bryan S, Dukart G et al. Mitoxantrone in malignant lymphoma. Invest New Drugs 1985;3:219–222.[Medline]
17. Silver RT, Case DC Jr, Wheeler RH et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin’s lymphoma and Hodgkin’s disease. J Clin Oncol 1991;9:754–761.[Abstract]
18. OSI Pharmaceuticals Medical Information Services. Novantrone and cardiotoxicity. Melville, NY: OSI Pharmaceuticals, 2003.
19. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992;10:790–794.[Abstract/Free Full Text]
20. Hochster HS, Kim KM, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin’s low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992;10:28–32.[Abstract]
21. Zinzani PL, Lauria F, Rondelli D et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin’s lymphoma. Ann Oncol 1993;4:575–578.[Abstract/Free Full Text]
22. Gregory SA, Venugopal P, Adler S et al Combined fludarabine, mitoxantrone, and rituximab achieves a high response as initial treatment for advanced low grade non-Hodgkin’s lymphoma (LGNHL). Blood 2002;100:362a, abstract 1401.
23. McLaughlin P, Hagemeister FB, Romaguera JE et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996;14:1262–1268.[Abstract/Free Full Text]
24. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101–106.[Abstract/Free Full Text]
25. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268–276.[Abstract/Free Full Text]
26. Czuczman MS, Grillo-Lopez AJ, McLaughlin P et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001;12:109–114.[Abstract/Free Full Text]
27. Czuczman MS, Fallon A, Mohr A et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29(suppl 2):36–40.
28. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856–862.[Abstract/Free Full Text]
29. DeVita VT Jr, Canellos GP, Chabner B et al. Advance diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975;1:248–250.[CrossRef][Medline]
30. Dreyling MH, Forstpointner R, Repp R et al. Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma—final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Blood 2003;102:103a, abstract 351.
31. Zinzani PL, Pulsoni A, Perrotti A et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654–2661.
32. Lichtman SM, Kolitz J, Budman DR et al. Treatment of aggressive non-Hodgkin’s lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP). Am J Clin Oncol 2001;24:360–362.[CrossRef][Medline]
33. Coleman M, Furman R, Niesvizky R et al. TOP-M chemotherapy (Thiotepa, Oncovin [Vincristine], Prednisone, Mitoxantrone) plus Ritoximab for marginal zone lymphoma. Blood 2004;104: abstract 4600.
34. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001;19:3918–3928.[Abstract/Free Full Text]
35. Bexxar [package insert]. Seattle: Corixa Corp and Philadelphia: GlaxoSmithKline, 2003.
36. Witzig TE, White CA, Gordon LI et al. Final results of a randomized controlled study of the ZevalinTM radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL. Blood 2000;96:831a.
37. Zevalin [package insert]. San Diego: IDEC Pharmaceuticals Corp, 2002.

This Article Abstract Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hagemeister, F. Articles by Zinzani, P. L. Search for Related Content PubMed PubMed Citation Articles by Hagemeister, F. Articles by Zinzani, P. L.